The U.S. Food and Drug Administration on Sept. 20 approved South Korean drugmaker Samsung Bioepis Co. Ltd. and Biogen Inc.’s biosimilar rival to Roche Holding AG’s blockbuster eye medicine Lucentis.
AbbVie is partnering with biotechnology firm REGENXBIO to develop and commercialize a new drug that could treat a wide range of eye diseases, including wet age-related macular degeneration (wet AMD).
Topline results from Outlook Therapeutics’ pivotal Phase III NORSE TWO safety and efficacy trial show the biopharmaceutical company’s ONS-5010/Lytenava (bevacizumab) significantly improved outcomes in patients with neovascular age-related macular degeneration.
REGENXBIO Inc. provided an update on the RGX-314 programs, including the announcement that the pivotal program for RGX-314 for the treatment of wet age-related macular degeneration (wet AMD) is active.
Novartis received approval from the U.S. Food and Drug Administration for the Swiss pharmaceuticals company’s drug Beovu to treat a cause of vision loss.
Harnessing the increasingly important applications of artificial intelligence, researchers from Genentech and parent company Roche have developed what is being called the first “deep learning model” that can predict which patients with diabetic retinopathy will progress the fastest.
Novartis has teamed up with celebrity interior designer Nate Berkus to launch My Home in Sight, a program that aims to raise awareness of the daily impact of wet age-related macular degeneration and empower those living with wet AMD and their caregivers to make simple, functional changes to support safety and independence at home.
The U.S. FDA approved Regeneron Pharmaceuticals Inc.’s Eylea (aflibercept) Injection for all stages of diabetic retinopathy, which is the leading cause of vision loss in diabetic patients.
Novartis announced that the U.S. Food and Drug Administration accepted the company’s Biologics License Application for brolucizumab (RTH258) for the treatment of wet age-related macular degeneration.
Days after rejecting Regeneron’s attempt to secure a supplemental approval for Eylea, the FDA approved a new dosing label for the drug in wet age-related macular degeneration (wet AMD).